ITI Test To Help Rule Out Heart Attacks Has $180 Mil. U.S. Market Potential
This article was originally published in The Gray Sheet
Executive Summary
Ischemia Technologies, Inc. (ITI) plans to sell its Albumin Cobalt Binding (ACB) test for $30 when it begins a controlled market release in March
You may also be interested in...
Inverness buys ischemia test
In vitro diagnostic blood test for use with troponin protein tests and electrocardiograms to help rule out heart attacks is acquired by Inverness under a $22.4 mil., all-stock deal to purchase developer Ischemia Technologies. The Ischemia Modified Albumin test was cleared via 510(k) in February 2003. The $30 test addresses a market of roughly 6 mil. patients in the U.S. who present with chest pains at emergency rooms each year. Privately held ITI had 2004 revenue of $1 mil. (1"The Gray Sheet" Feb. 24, 2003, p. 17)...
Inverness buys ischemia test
In vitro diagnostic blood test for use with troponin protein tests and electrocardiograms to help rule out heart attacks is acquired by Inverness under a $22.4 mil., all-stock deal to purchase developer Ischemia Technologies. The Ischemia Modified Albumin test was cleared via 510(k) in February 2003. The $30 test addresses a market of roughly 6 mil. patients in the U.S. who present with chest pains at emergency rooms each year. Privately held ITI had 2004 revenue of $1 mil. (1"The Gray Sheet" Feb. 24, 2003, p. 17)...
ACB Cardiac Marker May Receive Same Reimbursement Rate As BNP – Root
A modified albumin point-of-care test for ruling out heart attacks likely will receive similar reimbursement to the $47 rate for B-type natriuretic peptide tests, according to Charles Root, president of consulting firm MCF Compliance